Abstract
The occurrence of primary hepatocellular carcinoma (HCC) in patients with hereditary
hemochromatosis (HH) is well known. Thereby, the development of liver cirrhosis seems
to be a prerequisite. Whether or not a hepatic iron overload in the context of hereditary
hemochromatosis is an independent risk factor for HCC remains unclear. To date there
are only a few reports about HCC arising in non-cirrhotic livers in the presence of
HH. We report the case of a 64-year-old man who presented to our outpatient clinic
with HCC. Liver cirrhosis could be excluded. Detailed exploration of the patient’s
history revealed that he had been treated by venesection for about 10 years up to
15 years ago. Subsequent investigations showed an elevated serum ferritin and transferrin
saturation. The diagnosis of HH was confirmed by genetic testing, with homozygosity
for the Cys282Tyr mutation. The patient received palliative chemotherapy and finally
died 15 months after initial diagnosis of HCC.
Zusammenfassung
Das erhöhte Risiko für die Entstehung von hepatozellulären Karzinomen (HCC) bei Patienten
mit hereditärer Hämochromatose (HH) ist weithin bekannt. Voraussetzung hierzu scheint
das Vorliegen einer Leberzirrhose zu sein. Ob bei Patienten mit HH eine Eisenüberladung
der Leber unabhängig von zirrhotischen Veränderungen bereits einen eigenen Risikofaktor
für HCC darstellt, bleibt unklar. Bislang existieren nur wenige Fallberichte über
HCC bei HH in nichtzirrhotischen Lebern. Wir berichten über einen 64-jährigen Mann,
der sich zur Behandlung eines HCC in unserer onkologischen Tagesklinik vorstellte.
Eine Leberzirrhose konnte ausgeschlossen werden. Eine ausführliche Anamnese erbrachte,
dass er bis vor 15 Jahren über einen Zeitraum von etwa 10 Jahren mit Aderlässen behandelt
worden war. Weiterführende Untersuchungen ergaben erhöhte Werte für Serum Ferritin
und Transferrinsättigung. Die Diagnose einer HH konnte durch eine Genanalyse bestätigt
werden. Der Patient wies eine Homozygotie für die Mutation in Position Cys282Tyr auf.
Er wurde palliativ chemotherapiert und verstarb schließlich 15 Monate nach Diagnosestellung.
Key words
Hepatocellular carcinoma - hemochromatosis - liver cirrhosis - iron overload
Schlüsselwörter
Hepatozelluläres Karzinom - Hämochromatose - Leberzirrhose - Eisenüberladung
References
1
Kew M C.
Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African
blacks.
Gastroenterology.
1989;
44
136-139
2
Kew M C, Popper H.
Relationship between hepatocellular carcinoma and cirrhosis.
Semin Liver Dis.
1984;
44
136-146
3
Cauza E, Peck-Radosavljevic M, Ulrich-Pur H. et al .
Mutations of the HFE gene in patients with hepatocellular carcinoma.
Am J Gastroenterol.
2003;
44
442-447
4
Niederau C, Fischer R, Sonnenberg A. et al .
Survival and causes of death in cirrhotic and in noncirrhotic patients with primary
hemochromatosis.
N Engl J Med.
1985;
44
1256-1262
5
Elmberg M, Hultcrantz R, Ekbom A. et al .
Cancer risk in patients with hereditary hemochromatosis and in their first-degree
relatives.
Gastroenterology.
2003;
44
1733-1741
6
Hsing A W, McLaughlin J K, Olsen J H. et al .
Cancer risk following primary hemochromatosis: a population-based cohort study in
Denmark.
Int J Cancer.
1995;
44
160-162
7
Feder J N, Gnirke A, Thomas W. et al .
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.
Nat Genet.
1996;
44
399-408
8
Carella M, D’Ambrosio L, Totaro A. et al .
Mutation analysis of the HLA-H gene in Italian hemochromatosis patients.
Am J Hum Genet.
1997;
44
828-832
9
Nielsen P, Carpinteiro S, Fischer R. et al .
Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary
haemochromatosis and in control subjects from Northern Germany.
Br J Haematol.
1998;
44
842-845
10
Merryweather-Clarke A T, Pointon J J, Shearman J D. et al .
Global prevalence of putative haemochromatosis mutations.
J Med Genet.
1997;
44
275-278
11
Pietrangelo A.
Hereditary hemochromatosis - a new look at an old disease.
N Engl J Med.
2004;
44
2283-2297
12
Beutler E, Felitti V, Gelbart T. et al .
The effect of HFE genotypes on measurements of iron overload in patients attending
a health appraisal clinic.
Ann Intern Med.
2000;
44
329-337
13
Koziol J A, Felitti V J, Beutler E.
The effect of HFE genotypes on measurements of iron overload.
Ann Intern Med.
2002;
44
700-701
14
Guyader D, Gandon Y, Deugnier Y. et al .
Evaluation of computed tomography in the assessment of liver iron overload. A study
of 46 cases of idiopathic hemochromatosis.
Gastroenterology.
1989;
44
737-743
15
Niederau C, Strohmeyer G, Stremmel W.
Epidemiology, clinical spectrum and prognosis of hemochromatosis.
Adv Exp Med Biol.
1994;
44
293-302
16
Fargion S, Mandelli C, Piperno A. et al .
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis.
Hepatology.
1992;
44
655-659
17
Niederau C, Fischer R, Purschel A. et al .
Long-term survival in patients with hereditary hemochromatosis.
Gastroenterology.
1996;
44
1107-1119
18
Blumberg R S, Chopra S, Ibrahim R. et al .
Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis.
Gastroenterology.
1988;
44
1399-1402
19
Llovet J M, Burroughs A, Bruix J.
Hepatocellular carcinoma.
Lancet.
2003;
44
1907-1917
20
Fracanzani A L, Conte D, Fraquelli M. et al .
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis
in comparison to matched control patients with non-iron-related chronic liver disease.
Hepatology.
2001;
44
647-651
21
Britto M R, Thomas L A, Balaratnam N. et al .
Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis.
Scand J Gastroenterol.
2000;
44
889-893
22
Deugnier Y M, Guyader D, Crantock L. et al .
Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic
study of 54 cases.
Gastroenterology.
1993;
44
228-234
23
Goh J, Callagy G, McEntee G. et al .
Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis:
three case reports and review of literature.
Eur J Gastroenterol Hepatol.
1999;
44
915-919
24
Brage A, Tome S, Figueruela B. et al .
Hepatoma in a 40-year old male with hereditary hemochromatosis in the absence of cirrhosis.
Implications of molecular diagnosis.
Rev Esp Enferm Dig.
2002;
44
493-499
25
Meneghini R.
Iron homeostasis, oxidative stress, and DNA damage.
Free Radic Biol Med.
1997;
44
783-792
26
Esterbauer H.
Cytotoxicity and genotoxicity of lipid-oxidation products.
Am J Clin Nutr.
1993;
44
779-786
27
Hann H W, Stahlhut M W, Hann C L.
Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in
human hepatoma cell lines.
Hepatology.
1990;
44
566-569
28
Rothenberg B E, Voland J R.
Beta2 knockout mice develop parenchymal iron overload: A putative role for class I
genes of the major histocompatibility complex in iron metabolism.
Proc Natl Acad Sci USA.
1996;
44
1529-1534
29
Chapoutot C, Esslimani M, Joomaye Z. et al .
Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis.
Gut.
2000;
44
711-714
30
Ganne-Carrie N, Christidis C, Chastang C. et al .
Liver iron is predictive of death in alcoholic cirrhosis: A multivariate study of
229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective
follow up study.
Gut.
2000;
44
277-282
31
Tavill A.
Diagnosis and management of hemochromatosis.
Hepatology.
2001;
44
1321-1328
32
Pleass H, Garden O J.
Early diagnosis of hepatocellular carcinoma in hemochromatosis influences surgical
management.
Scot Med J.
1998;
44
114-115
33
Muting D, Kalk J F, Fischer R. et al .
Spontaneous regression of oesophageal varices after long-term conservative treatment:
Retrospective study in 20 patients with alcoholic liver cirrhosis, post-hepatitic
cirrhosis and haemochromatosis with cirrhosis.
J Hepatol.
1990;
44
158-162
34
Ioannou G N, Kowdley K V.
Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen?.
Clin Gastroenterol Hepatol.
2003;
44
246-248
35
Kowdley K V.
Iron, hemochromatosis, and hepatocellular carcinoma.
Gastroenterology.
2004;
44
79-86
MD Stefan von Delius
Klinikum rechts der Isar, II. Medizinische Klinik, Station 2/10
Ismaninger Str. 15
81675 München
Germany
Phone: ++ 49/89/41 40-22 51
Fax: ++ 49/89/41 40-49 64
Email: stefan_ruckert@yahoo.de